AbCellera Biologics (ABCL) Stock Forecast: What Could Drive It in 2026
Short answer
What is actually driving AbCellera Biologics (ABCL) right now is Own-pipeline catalysts in 2026: AbCellera has two internal candidates in the clinic with near-term readouts: ABCL-635 (a potential first-in-class NK3R antibody for menopausal hot flashes) with top-line Phase 2 data guided to Q3 2026, and ABCL-575 for atopic dermatitis with Phase 1 top-line data expected in Q4 2026. Revenue (Q1 2026) is ~$8.3M (up from ~$4.2M yr-ago). If that keeps playing out, the setup is favourable; the risk to it is abCellera is unprofitable and burning cash, posting a net loss of roughly $43M in Q1 2026 against only about $8M of quarterly revenue, so the market value rests on future clinical success rather than current earnings. No one can predict where ABCL trades, and Walnut does not publish targets, so treat this as a scenario, not a price target or prediction.
What could drive AbCellera Biologics (ABCL) higher?
1. Own-pipeline catalysts in 2026
AbCellera has two internal candidates in the clinic with near-term readouts: ABCL-635 (a potential first-in-class NK3R antibody for menopausal hot flashes) with top-line Phase 2 data guided to Q3 2026, and ABCL-575 for atopic dermatitis with Phase 1 top-line data expected in Q4 2026. Positive interim Phase 1 ABCL-635 data showed a clean safety profile and an ~24-day half-life supporting once-monthly dosing. These readouts are the dominant value drivers for the year.
2. Deep cash runway
The company ended Q1 2026 with about $531M in cash and marketable securities and roughly $655M in total available liquidity including non-dilutive government funding. That balance sheet lets it push multiple programs through the clinic without immediate reliance on dilutive raises, a meaningful advantage for a pre-revenue-scale biotech.
3. Platform and royalty optionality
AbCellera has completed over 100 antibody-discovery programs and retains downstream milestone and royalty rights across many partner programs, plus blue-chip relationships (Eli Lilly, Regeneron, AbbVie, Biogen). Any partner-program approvals could add royalty streams on top of the internal pipeline, giving a second, lower-cost source of potential upside.
4. Expanding earlier-stage pipeline
Beyond the two clinical assets, AbCellera is advancing ABCL-688 and ABCL-386 through IND-enabling work with a target of entering clinical trials by 2027, and aims to add new development candidates. This widening internal pipeline is how management intends to build a durable, multi-shot-on-goal drug portfolio rather than a single-asset bet.
What could weigh on ABCL?
AbCellera is unprofitable and burning cash, posting a net loss of roughly $43M in Q1 2026 against only about $8M of quarterly revenue, so the market value rests on future clinical success rather than current earnings. Its stock is highly binary: a miss on the ABCL-635 or ABCL-575 readouts could sharply reset the valuation. Platform revenue has fallen far from its pandemic-era peak (when Lilly antibody royalties were large) and is lumpy and partner-dependent. Drug development carries the usual risks of trial failure, regulatory delay and competition in crowded indications, and while the cash runway is long, sustained losses could eventually require dilutive financing.
Where ABCL trades today
A forecast starts from where the stock actually is. These are ABCL's current figures, not a projection: the drivers and risks above are what would move them.
Snapshot for ABCL as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
How to think about a ABCL forecast
Rather than chasing a price target, it tends to help to weigh the drivers above against the risks, decide how long you are willing to hold, and size the position so a wrong call is survivable. A “forecast” is really a probability-weighted view of those drivers playing out, not a number.
For the full picture, see the ABCL guide and whether ABCL is a buy. In Walnut you can pressure-test the thesis against your real portfolio.
The bottom line on the ABCL outlook
The bottom line: what is driving AbCellera Biologics (ABCL) is Own-pipeline catalysts in 2026, with revenue (q1 2026) at ~$8.3M (up from ~$4.2M yr-ago). If that keeps playing out the setup is favourable; the risk is abCellera is unprofitable and burning cash, posting a net loss of roughly $43M in Q1 2026 against only about $8M of quarterly revenue, so the market value rests on future clinical success rather than current earnings. No one can predict the price, so treat any ABCL forecast as a scenario, not a target or prediction, and decide from your own thesis and time horizon. Walnut is not an investment adviser.
Build a basket around ABCL with Walnut
Use AbCellera Biologics as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
What is the forecast for AbCellera Biologics (ABCL)?
+
No one can reliably predict where ABCL will trade, and Walnut does not publish price targets. What is more useful is the setup: the drivers that could push AbCellera Biologics higher and the risks that could weigh on it. This page lays out both so you can form your own view. Not a recommendation.
What could drive ABCL higher?
+
The main growth drivers are Own-pipeline catalysts in 2026; Deep cash runway; Platform and royalty optionality. Whether they play out is the real question, not a guaranteed path.
What are the risks to ABCL?
+
AbCellera is unprofitable and burning cash, posting a net loss of roughly $43M in Q1 2026 against only about $8M of quarterly revenue, so the market value rests on future clinical success rather than current earnings. Its stock is highly binary: a miss on the ABCL-635 or ABCL-575 readouts could sharply reset the valuation. Platform revenue has fallen far from its pandemic-era peak (when Lilly antibody royalties were large) and is lumpy and partner-dependent. Drug development carries the usual risks of trial failure, regulatory delay and competition in crowded indications, and while the cash runway is long, sustained losses could eventually require dilutive financing.
Will ABCL stock go up in 2026?
+
Nobody knows, and anyone who says they do is guessing. AbCellera Biologics's direction depends on whether the drivers above outweigh the risks, plus the broader market. Focus on the thesis and your time horizon rather than a single-year call.
Is ABCL a buy?
+
That depends on your thesis, time horizon, and what you already own, not on a forecast. See the ABCL "is it a buy?" page for a framework. Walnut is not an investment adviser.
Walnut is informational, not investment advice. This page describes drivers and risks; it is not a price forecast, target, or recommendation. Markets are uncertain and past performance does not predict future results.